VAM
ALNY icon

Visium Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Visium Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-792,295
Closed -$49.7M – 348
2016
Q1 		$49.7M Buy
792,295
+690,948
+682% +$45.9M 0.85% 22
2015
Q4 		$9.54M Buy
+101,347
New +$9.4M 0.14% 170
2015
Q3 		– Sell
-93,684
Closed -$11.2M – 896
2015
Q2 		$11.2M Buy
93,684
+87,167
+1,338% +$10.4M 0.16% 136
2015
Q1 		$681K Buy
+6,517
New +$660K 0.01% 594

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Visium Asset Management's ALNY Position: Q2 2016 in Review

Visium Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2016, closing a stake of 792,295 shares — an estimated $49.7M sold.

Visium Asset Management first reported a position in ALNY in Q1 2015 and held it in 4 quarters. The position peaked at $49.7M in Q1 2016. 249 funds tracked by Wall St. Rank hold ALNY as of Q2 2016.

  • Visium Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Visium Asset Management sold 792,295 Alnylam Pharmaceuticals shares in Q2 2016, an estimated $49.7M.
  • Visium Asset Management first reported a position in Alnylam Pharmaceuticals in Q1 2015 and held it in 4 quarters.
  • Visium Asset Management's Alnylam Pharmaceuticals position peaked at $49.7M in Q1 2016.
  • 249 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2016.

Based on Visium Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.